Ontology type: schema:ScholarlyArticle
2005-08
AUTHORSElizabeth A. Calhoun, Glen T. Schumock, June M. McKoy, Simon Pickard, Karen A. Fitzner, Elizabeth A. Heckinger, Eowyn F. Powell, Kathyrn R. McCaffrey, Charles L. Bennett
ABSTRACTRecombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40–60%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature. More... »
PAGES767-775
http://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003
DOIhttp://dx.doi.org/10.2165/00019053-200523080-00003
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1038420911
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16097839
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Public Health and Health Services",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Attention Deficit Disorder with Hyperactivity",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Carcinoma, Small Cell",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Chicago",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Costs and Cost Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "England",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Granulocyte Colony-Stimulating Factor",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lung Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Midwestern United States",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neutropenia",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Quality of Life",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Recombinant Proteins",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.185648.6",
"name": [
"Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "Calhoun",
"givenName": "Elizabeth A.",
"id": "sg:person.016654752007.02",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016654752007.02"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.185648.6",
"name": [
"The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "Schumock",
"givenName": "Glen T.",
"id": "sg:person.01331114412.87",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331114412.87"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.16753.36",
"name": [
"Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "McKoy",
"givenName": "June M.",
"id": "sg:person.01330740160.15",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330740160.15"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.185648.6",
"name": [
"The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "Pickard",
"givenName": "Simon",
"id": "sg:person.01152461067.24",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152461067.24"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.16753.36",
"name": [
"Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "Fitzner",
"givenName": "Karen A.",
"id": "sg:person.01220574267.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220574267.85"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.16753.36",
"name": [
"Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "Heckinger",
"givenName": "Elizabeth A.",
"id": "sg:person.0615632750.10",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615632750.10"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.16753.36",
"name": [
"Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "Powell",
"givenName": "Eowyn F.",
"id": "sg:person.01335022667.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335022667.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.16753.36",
"name": [
"Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "McCaffrey",
"givenName": "Kathyrn R.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA",
"id": "http://www.grid.ac/institutes/grid.16753.36",
"name": [
"Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
],
"type": "Organization"
},
"familyName": "Bennett",
"givenName": "Charles L.",
"id": "sg:person.01100705232.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100705232.37"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.2165/00019053-199400062-00008",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019047021",
"https://doi.org/10.2165/00019053-199400062-00008"
],
"type": "CreativeWork"
}
],
"datePublished": "2005-08",
"datePublishedReg": "2005-08-01",
"description": "Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40\u201360%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature.",
"genre": "article",
"id": "sg:pub.10.2165/00019053-200523080-00003",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1102812",
"issn": [
"1170-7690",
"1179-2027"
],
"name": "PharmacoEconomics",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "8",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "23"
}
],
"keywords": [
"small cell lung cancer",
"granulocyte colony-stimulating factor",
"febrile neutropenia",
"cell lung cancer",
"primary prophylaxis",
"colony-stimulating factor",
"chemotherapeutic regimens",
"lung cancer",
"cancer patients",
"chemotherapy-associated febrile neutropenia",
"evidence-based clinical guidelines",
"FN rate",
"chemotherapy-induced neutropenia",
"productivity-related costs",
"use of filgrastim",
"severe febrile neutropenia",
"recombinant granulocyte colony-stimulating factor",
"future cost-effectiveness studies",
"cost-effectiveness ratio",
"healthcare payer perspective",
"cost-effectiveness studies",
"cost-effectiveness evidence",
"cost-effectiveness threshold",
"clinical guidelines",
"payer perspective",
"patients",
"prophylaxis",
"regimens",
"societal perspective",
"CSF",
"available evidence",
"pocket costs",
"indirect costs",
"neutropenia",
"risk threshold",
"American Society",
"cancer",
"same recommendations",
"pegfilgrastim",
"medications",
"filgrastim",
"ASCO",
"severity",
"evidence",
"rate",
"factors",
"CSFs",
"duration",
"use",
"guidelines",
"threshold",
"recommendations",
"half",
"study",
"benefits",
"people",
"literature",
"inclusion",
"ratio",
"importance",
"circumstances",
"cost",
"economic considerations",
"perspective",
"decisions",
"basis",
"consideration",
"current rules",
"society",
"range",
"economic benefits",
"rules",
"paper",
"Clinical Oncology (ASCO) evidence-based clinical guidelines",
"Oncology (ASCO) evidence-based clinical guidelines",
"available cost-effectiveness evidence",
"base-case rates"
],
"name": "Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer",
"pagination": "767-775",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1038420911"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.2165/00019053-200523080-00003"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16097839"
]
}
],
"sameAs": [
"https://doi.org/10.2165/00019053-200523080-00003",
"https://app.dimensions.ai/details/publication/pub.1038420911"
],
"sdDataset": "articles",
"sdDatePublished": "2022-01-01T18:14",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_397.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.2165/00019053-200523080-00003"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'
This table displays all metadata directly associated to this object as RDF triples.
259 TRIPLES
22 PREDICATES
119 URIs
109 LITERALS
20 BLANK NODES